Advisory Board Member

Dr Olivier Wong

Olivier is a specialist in study design from an HTA and payer perspective, from early-stage to submission. Supporting life sciences companies gain a comprehensive understanding of regulatory and HTA requirements, aligning their drug development programmes to meet the requirements of regulators and payers alike.

Key Areas Of Expertise
  • Study design from an HTA & payer perspective from early-stage to submission
  • Team working with regulators
  • Advisor for the payer industries for emerging markets (disease management, HTA, guidelines)
  • Effect size and risk assessment at the global level
  • Joint regulator HTA early engagements
  • The network of international HTA and payers
  • Efficiency implementation in health care organization & strategic input
Before Joining The NDA Advisory Board

Olivier was a member of the French Transparency Committee, the Governance Committee (Department of Health) and the National Guideline Committee [Drug National Agency and HAS]. He also worked for the Ministries of Health, French Social Security and Payer Organizations Consultant in emerging countries.

MD, Master of Science, C.E.S.A.M.

Dr Olivier Wong

LinkedIn

 

Stay up to date

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World